Patents by Inventor Isabelle Coste-Invernizzi

Isabelle Coste-Invernizzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzoimidazole Derivatives As Anticancer Agents
    Publication number: 20220348587
    Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing the compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.
    Type: Application
    Filed: June 3, 2022
    Publication date: November 3, 2022
    Applicants: CENTRE LEON BERARD, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Toufic RENNO, Isabelle COSTE-INVERNIZZI, Stéphane GIRAUD, Serge LEBECQUE
  • Benzoimidazole derivatives as anticancer agents
    Patent number: 11384081
    Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: July 12, 2022
    Assignees: CENTRE LEON BERARD, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Toufic Renno, Isabelle Coste-Invernizzi, Stéphane Giraud, Serge Lebecque
  • BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS
    Publication number: 20210292328
    Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.
    Type: Application
    Filed: September 20, 2017
    Publication date: September 23, 2021
    Applicants: CENTRE LEON BERARD, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Toufic RENNO, Isabelle COSTE-INVERNIZZI, Stéphane GIRAUD, Serge LEBECQUE
  • Treatment of cancer by inhibition of the MYD88/ERK MAP kinase interaction
    Patent number: 9683986
    Abstract: A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: June 20, 2017
    Assignees: CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, HOSPICES CIVILS DE LYON, INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Alain Kfoury, Isabelle Coste-Invernizzi, Serge Lebecque, Toufic Renno
  • TREATMENT OF CANCER BY INHIBITION OF THE MYD88/ERK MAP KINASE INTERACTION
    Publication number: 20140329261
    Abstract: A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE.
    Type: Application
    Filed: December 17, 2012
    Publication date: November 6, 2014
    Applicants: CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, HOSPICES CIVILS DE LYON, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Alain Kfoury, Isabelle Coste-Invernizzi, Serge Lebecque, Toufic Renno
  • COMBINATION OF A TLR3 LIGAND AND A CHEMOTHERAPY AGENT WHICH ACTS ON THE INTRINSIC "APOPTOSIS" PATHWAY IN THE TREATMENT OF CANCER
    Publication number: 20120045523
    Abstract: The present invention relates to a drug comprising separately or together (i) a TLR3 ligand and (ii) a chemotherapeutic agent that acts on the intrinsic apoptotic pathway, for simultaneous or sequential administration in the treatment of cancer, wherein the chemotherapeutic agent is selected from topoisomerase II inhibitors, platinum-derived alkylating agents and PI3 kinase inhibitors.
    Type: Application
    Filed: July 31, 2009
    Publication date: February 23, 2012
    Applicants: UNIVERSITE CLAUDE BERNARD LYON I, HOSPICES CIVILS DE LYON
    Inventors: Serge Lebecque, Charles Dumontet, Yves Pacheco, Claire Rodriguez-Lafrasse, Florent Toscano, Yann Estornes, Francois Virard, Isabelle Coste-Invernizzi, Toufic Renno
  • INDUCTION OF APOPTOSIS IN TOLL-LIKE RECEPTOR EXPRESSING TUMOR CELLS
    Publication number: 20090285779
    Abstract: Some types of cancer cells express one or more Toll-like receptors (TLRs). These TLRs are therapeutic targets. The invention relates to methods for treating Toll-like receptor expressing cancers and tumor cells by selecting a TLR expressing tumor cell and contacting the cell with a therapeutically effective amount of a TLR ligand. The invention particularly relates to methods for treating TLR3 expressing cancers and tumor cells using TLR3 agonists.
    Type: Application
    Filed: December 6, 2007
    Publication date: November 19, 2009
    Inventors: SERGE LEBECQUE, Toufic Renno, Bruno Salaun, Isabelle Coste-Invernizzi, Marie-Clotilde Rissoan
  • Sporadic tumor mouse model for drug discovery
    Publication number: 20060259989
    Abstract: The present invention relates to a transgenic mouse containing a latent oncogenic ?-catenin allele capable of spontaneous activation in vivo. The transgenic mouse is useful for the identification of compounds and immunotherapies for the prevention, treatment and/or cure of various forms of cancer associated with ?-catenin activation.
    Type: Application
    Filed: March 9, 2006
    Publication date: November 16, 2006
    Inventors: Isabelle Coste-Invernizzi, Toufic Renno
  • Induction of apoptosis in toll-like receptor expressing tumor cells
    Publication number: 20060147456
    Abstract: Some types of cancer cells express one or more Toll-like receptors (TLRs). These TLRs are therapeutic targets. The invention relates to methods for treating Toll-like receptor expressing cancers and tumor cells by selecting a TLR expressing tumor cell and contacting the cell with a therapeutically effective amount of a TLR ligand. The invention particularly relates to methods for treating TLR3 expressing cancers and tumor cells using TLR3 agonists.
    Type: Application
    Filed: July 19, 2005
    Publication date: July 6, 2006
    Inventors: Serge Lebecque, Toufic Renno, Bruno Salaun, Isabelle Coste-Invernizzi, Marie-Clotilde Rissoan
  • MyD88 as a therapeutic target for cancer
    Publication number: 20060141490
    Abstract: The invention relates to methods for identifying anti-cancer agents using MyD88 as a therapeutic target.
    Type: Application
    Filed: July 15, 2005
    Publication date: June 29, 2006
    Inventors: Isabelle Coste-Invernizzi, Toufic Renno